logo transparent gif
top_white_spacer
Home Latest Stock Forum Topics MyCorner - Personal Stocks Porfolio Stock Lists Investor Insights Investor Research & Links Dynamic Stock Charting FREE Registration About Us top spacer top spacer
 User Password Auto-Login
Enter Stock
 
righttip
branding

Back
First   1-20 of 310   Older>   Last  
Latest Forum Topics / Trendlines    Last:0.052 --  Post Reply
Frasers Cpt Tr

treetops
Elite
06-Aug-2026 11:02     
 
treetops About Contact  Quote this Post! Style: Flexible   Mood: cool
Yells: "Moments Today, Memories Tomorrow!"
  x 0
  x 0

 Alert Admin 		The more rights issues they conduct, the cheaper the rights price gets, and the more diluted the shares become.

LoudShout      ( Date: 06-Aug-2026 11:00) Posted:

This Co screwed many investors since its IPO based on its performance:
 
AI Overview
 
 
The Trendlines Group (SGX:42T) was listed on the Catalist board of the Singapore Exchange on November 26, 2015, with an IPO price of S$0.33 per share, and has not declared or paid any dividends since its initial public offering. 
 
IPO Details
  • Listing Date: November 26, 2015
  • IPO/Placement Price: S$0.33 per share
  • Shares Offered: 75.76 million placement shares 
 
Subsequent Rights Issues
The company has undertaken several rights issues to raise capital: 
  • 2019 Rights Issue: Offered on a 1-for-9 basis at an issue price of S$0.1050 per rights share.
  • 2024 Rights Issue: Offered on a 1-for-14 basis at an issue price of S$0.06 per rights share.
  • 2025 Rights Issue: Offered on a 1-for-8 basis at an issue price of S$0.0285 per rights share. 
 
Dividend History
  • Dividends Declared: None. The company has maintained a policy of reinvesting capital into its medical and agricultural technology incubator portfolio rather than distributing payouts, and no dividends have been recommended or paid. 


 

 Useful To Me  Not Useful To Me
LoudShout
Master
06-Aug-2026 11:00     
 
LoudShout About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin
This Co screwed many investors since its IPO based on its performance:
 
AI Overview
 
 
The Trendlines Group (SGX:42T) was listed on the Catalist board of the Singapore Exchange on November 26, 2015, with an IPO price of S$0.33 per share, and has not declared or paid any dividends since its initial public offering. 
 
IPO Details
  • Listing Date: November 26, 2015
  • IPO/Placement Price: S$0.33 per share
  • Shares Offered: 75.76 million placement shares 
 
Subsequent Rights Issues
The company has undertaken several rights issues to raise capital: 
  • 2019 Rights Issue: Offered on a 1-for-9 basis at an issue price of S$0.1050 per rights share.
  • 2024 Rights Issue: Offered on a 1-for-14 basis at an issue price of S$0.06 per rights share.
  • 2025 Rights Issue: Offered on a 1-for-8 basis at an issue price of S$0.0285 per rights share. 
 
Dividend History
  • Dividends Declared: None. The company has maintained a policy of reinvesting capital into its medical and agricultural technology incubator portfolio rather than distributing payouts, and no dividends have been recommended or paid. 


 
 Useful To Me  Not Useful To Me


eric998
Supreme
06-Aug-2026 09:55     
 
eric998 About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		Shortists heard. Earnings can sustain?

Joelton      ( Date: 06-Aug-2026 09:54) Posted:



Trendlines back in the black with earnings of US$2.2 mil for 1HFY2026

The Trendlines Group (Trendlines) (SGX:42T) reports a net profit of US$2.2 million ($2.8 million) for 1HFY2026 ended June 30, as compared to a loss of US$3.5 million a year ago.

The turnaround in Trendlinesก ฆ bottom line was largely attributable to a net gain of US$5.6 million in the fair value of its portfolio companies.

Trendlines registered a gain of US$6.7 million due to the first-time valuation of its Singapore portfolio companies following its transition to investment entity accounting, of which the investments are now measured at fair value.

In addition, there was a further gain of US$3.1 million, driven by favourable fundraising terms and commercial or technological progress.

However, those gains were partially offset by a US$1 million decline in fair value from less favourable fundraising terms and commercial challenges at certain portfolio companies.

Meanwhile, seven portfolio companies were written off in 1HFY2026 due to a lack of funding, resulting in a fair value reduction of US$3.2 million.

Total assets increased roughly 6.77% from US$85.8 million as at Dec 31, 2025 to US$91.6 million as at June 30, mainly due to an increase in investments in portfolio companies.

Net asset value per share remains unchanged at 6 US cents as at June 30, with a slight increase in cash and cash equivalents to US$5.01 million in the same period.

ก ง As our portfolio continues to hit commercial and fundraising milestones, we remain focused on positioning our companies for strategic exits and delivering long-term value for all stakeholders,ก จ says Haim Brosh, CEO of Trendlines.

Shares in Trendlines closed 0.1 cent lower, or down 1.79% at 5.5 cents on Aug 5.

 Useful To Me  Not Useful To Me
Joelton
Supreme
06-Aug-2026 09:54     
 
Joelton About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin

Trendlines back in the black with earnings of US$2.2 mil for 1HFY2026

The Trendlines Group (Trendlines) (SGX:42T) reports a net profit of US$2.2 million ($2.8 million) for 1HFY2026 ended June 30, as compared to a loss of US$3.5 million a year ago.

The turnaround in Trendlinesก ฆ bottom line was largely attributable to a net gain of US$5.6 million in the fair value of its portfolio companies.

Trendlines registered a gain of US$6.7 million due to the first-time valuation of its Singapore portfolio companies following its transition to investment entity accounting, of which the investments are now measured at fair value.

In addition, there was a further gain of US$3.1 million, driven by favourable fundraising terms and commercial or technological progress.

However, those gains were partially offset by a US$1 million decline in fair value from less favourable fundraising terms and commercial challenges at certain portfolio companies.

Meanwhile, seven portfolio companies were written off in 1HFY2026 due to a lack of funding, resulting in a fair value reduction of US$3.2 million.

Total assets increased roughly 6.77% from US$85.8 million as at Dec 31, 2025 to US$91.6 million as at June 30, mainly due to an increase in investments in portfolio companies.

Net asset value per share remains unchanged at 6 US cents as at June 30, with a slight increase in cash and cash equivalents to US$5.01 million in the same period.

ก ง As our portfolio continues to hit commercial and fundraising milestones, we remain focused on positioning our companies for strategic exits and delivering long-term value for all stakeholders,ก จ says Haim Brosh, CEO of Trendlines.

Shares in Trendlines closed 0.1 cent lower, or down 1.79% at 5.5 cents on Aug 5.
 Useful To Me  Not Useful To Me
ahberngh
Elite
06-Aug-2026 09:52     
 
ahberngh About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		Invested 2016 at 17.6c, waitied for it to rocket
until I sold all in 2021 at 10-12c.
Never receive any dividend.
A few exits in the past (if I recall correctly) mostly $2M-5M range.
Just my observation, please dyodd.
 Useful To Me  Not Useful To Me


TraderBen
Supreme
06-Aug-2026 09:34     
 
TraderBen About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		SOP as always..

TraderBen      ( Date: 06-Aug-2026 08:52) Posted:

will open high and TRENDDOWN again

SmallSmall      ( Date: 06-Aug-2026 08:38) Posted:

Trendlines sustains profitability and increases portfolio company value

&bull The Group recorded net profit of US$2.2 million in H1 2026, compared to a loss of US$3.5 million in H1 2025.

&bull IFRS Portfolio Fair Value: US$83.4 million, compared to US$76.5 million as at 31 December 2025, representing a 9% increase in value non-IFRS Portfolio Fair Value: US$146.0 million, compared to US$127.7 million as at 31 December 2025, representing a 14% increase in value

&bull Portfolio companies continue to achieve commercial and fundraising milestones, highlighting their innovation and potential as we position ourselves for long-term value creation and strategic exits.
 Useful To Me  Not Useful To Me
LoudShout
Master
06-Aug-2026 09:00     
 
LoudShout About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		profit from fair value revaluation.

Negative cashflow..

Any dividends for shareholders since its IPO?

TraderBen      ( Date: 06-Aug-2026 08:52) Posted:

will open high and TRENDDOWN again

SmallSmall      ( Date: 06-Aug-2026 08:38) Posted:

Trendlines sustains profitability and increases portfolio company value

&bull The Group recorded net profit of US$2.2 million in H1 2026, compared to a loss of US$3.5 million in H1 2025.

&bull IFRS Portfolio Fair Value: US$83.4 million, compared to US$76.5 million as at 31 December 2025, representing a 9% increase in value non-IFRS Portfolio Fair Value: US$146.0 million, compared to US$127.7 million as at 31 December 2025, representing a 14% increase in value

&bull Portfolio companies continue to achieve commercial and fundraising milestones, highlighting their innovation and potential as we position ourselves for long-term value creation and strategic exits.
 Useful To Me  Not Useful To Me
TraderBen
Supreme
06-Aug-2026 08:52     
 
TraderBen About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		will open high and TRENDDOWN again

SmallSmall      ( Date: 06-Aug-2026 08:38) Posted:

Trendlines sustains profitability and increases portfolio company value

&bull The Group recorded net profit of US$2.2 million in H1 2026, compared to a loss of US$3.5 million in H1 2025.

&bull IFRS Portfolio Fair Value: US$83.4 million, compared to US$76.5 million as at 31 December 2025, representing a 9% increase in value non-IFRS Portfolio Fair Value: US$146.0 million, compared to US$127.7 million as at 31 December 2025, representing a 14% increase in value

&bull Portfolio companies continue to achieve commercial and fundraising milestones, highlighting their innovation and potential as we position ourselves for long-term value creation and strategic exits.
 Useful To Me  Not Useful To Me


SmallSmall
Supreme
06-Aug-2026 08:38     
 
SmallSmall About Contact  Quote this Post!  
  x 0
  x 1

 Alert Admin 		Trendlines sustains profitability and increases portfolio company value

&bull The Group recorded net profit of US$2.2 million in H1 2026, compared to a loss of US$3.5 million in H1 2025.

&bull IFRS Portfolio Fair Value: US$83.4 million, compared to US$76.5 million as at 31 December 2025, representing a 9% increase in value non-IFRS Portfolio Fair Value: US$146.0 million, compared to US$127.7 million as at 31 December 2025, representing a 14% increase in value

&bull Portfolio companies continue to achieve commercial and fundraising milestones, highlighting their innovation and potential as we position ourselves for long-term value creation and strategic exits.
 Useful To Me  Not Useful To Me
Newbie85
Veteran
15-Jul-2026 12:11     
 
Newbie85 About Contact  Quote this Post!  
  x 0
  x 1

 Alert Admin 		Trendline is a solid company. 

just wait for one of their stints to be bought over. 

easily going to rocket
 Useful To Me  Not Useful To Me
Joelton
Supreme
15-Jul-2026 08:48     
 
Joelton About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin

Trendlines portfolio company ElastiMed inks exclusive US distribution agreement with Nasdaq-listed Tactile Medical

The Trendlines Group (Trendlines) (SGX:42T) announced that its portfolio company, ElastiMed Limited, has entered into an exclusive US distribution agreement with Tactile Systems Technology, Inc. (Tactile Medical), which is a Nasdaq-listed medical technology company.

Under the agreement, Tactile Medical will be ElastiMed&rsquo s exclusive US distribution partner to bring MyoSleeve, a discreet, wearable non-pneumatic compression device for the lower leg, to Department of Veterans Affairs (VA) and Department of Defense (DoD) patients at select VA and DoD facilities across the US.

According to Trendlines, this agreement marks a major milestone in ElastiMed&rsquo s US commercial launch strategy, providing immediate access to a large, underserved patient population.

Trendlines add that ElastiMed&rsquo s MyoSleeve combines clinical-grade compression with comfort and connectivity in a breakthrough, low-profile wearable device, intended to promote compliance and support optimal clinical outcomes for the treatment of venous and lymphatic conditions.

&ldquo A commercial agreement with a Nasdaq-listed medical technology company is strong validation of ElastiMed&rsquo s technology and of Trendlines&rsquo model of transforming early-stage innovations into commercial businesses, supporting long-term value creation for our shareholders,&rdquo says Haim Brosh, CEO of Trendlines.

Shares of Trendlines closed flat at 5.8 cents on July 14.
 Useful To Me  Not Useful To Me
TraderBen
Supreme
06-Jul-2026 09:52     
 
TraderBen About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		no use one la.. even up also will go down one..

SmallSmall      ( Date: 06-Jul-2026 09:45) Posted:

Trendlines Medical Singapore Portfolio Company NICE Surgical Awarded U.S. Patent for Purse-String Stapler Enables intracorporeal purse-sting suturing, stapling, and resection in a single firing Singapore, Misgav, Israel &ndash 3 July 2026 &ndash

The Trendlines Group Ltd (SGX: 42T, OTCQX: TRNLY), (&ldquo Trendlines&rdquo ) an investment company focused on medtech and agrifood innovation, is pleased to announce that portfolio company NICE Surgical Solutions Pte Ltd (&ldquo NICE Surgical&rdquo ), a clinical-stage medical device company pioneering full intracorporeal anastomosis surgical instruments, has been officially granted the U.S. Patent No. 12,653,527 B2, for its purse-string stapler. NICE Surgical is based in Singapore and incubated by Trendlines&rsquo subsidiary, Trendlines Medical Singapore Pte Ltd (&ldquo Trendlines Medical Singapore&rdquo ). This newly granted patent covers the efficient application of a purse-string suture around the tissue adjacent to the open lumen during the colorectal surgery. The suture enables the effective closure of the colon, providing a full intracorporeal anastomosis at the completion of the surgery. The award of the patent validates NICE Surgical&rsquo s commitment to advance innovative medical solutions that improve the quality of life of patients. The patented technology enables colorectal surgery to be completed non-invasively, without an incision to the abdomen, as currently practiced. The use of NICE Surgical&rsquo s device potentially increases the efficiency in surgery and reduces surgical site infections, usually associated with surgical incisions. Haim Brosh, Trendlines&rsquo CEO said, &ldquo This patent is a testament to the dedication and ingenuity of the research and development team at NICE Surgical. With NICE Surgical&rsquo s development progression, including human clinical studies by Q4 2026, this milestone further strengthens the validated technology.&rdquo &ldquo Medical innovation transforms scientific discovery into better patient outcomes. I am excited that the grant of this patent acknowledges the novelty, ingenuity and potential societal value of our medical innovation,&rdquo commented co-founder and inventor, Eric Haas, MD, Chief of Colorectal Surgery at Houston Methodist Hospital. 

 Useful To Me  Not Useful To Me


SmallSmall
Supreme
06-Jul-2026 09:45     
 
SmallSmall About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		Trendlines Medical Singapore Portfolio Company NICE Surgical Awarded U.S. Patent for Purse-String Stapler Enables intracorporeal purse-sting suturing, stapling, and resection in a single firing Singapore, Misgav, Israel &ndash 3 July 2026 &ndash

The Trendlines Group Ltd (SGX: 42T, OTCQX: TRNLY), (&ldquo Trendlines&rdquo ) an investment company focused on medtech and agrifood innovation, is pleased to announce that portfolio company NICE Surgical Solutions Pte Ltd (&ldquo NICE Surgical&rdquo ), a clinical-stage medical device company pioneering full intracorporeal anastomosis surgical instruments, has been officially granted the U.S. Patent No. 12,653,527 B2, for its purse-string stapler. NICE Surgical is based in Singapore and incubated by Trendlines&rsquo subsidiary, Trendlines Medical Singapore Pte Ltd (&ldquo Trendlines Medical Singapore&rdquo ). This newly granted patent covers the efficient application of a purse-string suture around the tissue adjacent to the open lumen during the colorectal surgery. The suture enables the effective closure of the colon, providing a full intracorporeal anastomosis at the completion of the surgery. The award of the patent validates NICE Surgical&rsquo s commitment to advance innovative medical solutions that improve the quality of life of patients. The patented technology enables colorectal surgery to be completed non-invasively, without an incision to the abdomen, as currently practiced. The use of NICE Surgical&rsquo s device potentially increases the efficiency in surgery and reduces surgical site infections, usually associated with surgical incisions. Haim Brosh, Trendlines&rsquo CEO said, &ldquo This patent is a testament to the dedication and ingenuity of the research and development team at NICE Surgical. With NICE Surgical&rsquo s development progression, including human clinical studies by Q4 2026, this milestone further strengthens the validated technology.&rdquo &ldquo Medical innovation transforms scientific discovery into better patient outcomes. I am excited that the grant of this patent acknowledges the novelty, ingenuity and potential societal value of our medical innovation,&rdquo commented co-founder and inventor, Eric Haas, MD, Chief of Colorectal Surgery at Houston Methodist Hospital. 
 Useful To Me  Not Useful To Me
Joelton
Supreme
04-Jul-2026 14:06     
 
Joelton About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin

Trendlines portfolio company NICE Surgical granted US patent for purse-string stapler

The Trendlines Group (Trendlines) (SGX:42T) announced that its portfolio company, NICE Surgical Solutions Pte Ltd (NICE Surgical), a clinical-stage medical device company, has been officially granted the US patent for its purse-string stapler.

NICE Surgical is based in Singapore and incubated by Trendlines&rsquo subsidiary, Trendlines Medical Singapore.

According to Trendlines, this patented technology enables colorectal surgery to be completed non-invasively, without an incision to the abdomen, as currently practiced. The use of NICE Surgical&rsquo s device potentially increases the efficiency in surgery and reduces surgical site infections, usually associated with surgical incisions.

&ldquo This patent is a testament to the dedication and ingenuity of the research and development team at NICE Surgical. With NICE Surgical&rsquo s development progression, including human clinical studies by Q4 2026, this milestone further strengthens the validated technology,&rdquo says Haim Brosh, CEO of Trendlines.

Shares of Trendlines closed 0.1 cent higher, or 1.72% up at 5.9 cents on July 3.
 Useful To Me  Not Useful To Me
Joelton
Supreme
29-May-2026 10:39     
 
Joelton About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin

Trendlines portfolio company Phytolon closes US$23.6 mil Series B financing

The Trendlines Group (Trendlines) (SGX:42T) announced that its portfolio company, Phytolon, has closed its US$23.6 million Series B financing to commercialise its natural food colours in the United States.

Trendlines says that the Series B financing round for Phytolon was led by a strategic investor, whose identity has not yet been disclosed.

&ldquo This funding was structured in three stages, including the realization of SAFE investment vehicles made prior to this closing, with the bulk of the capital being secured during the final stage earlier this month. In addition to the lead investor, existing investors also participated in the round,&rdquo Trendlines add.

From Trendlines&rsquo point of view, the entry of a strategic lead investor at the commercialisation stage is a positive development for Phytolon.

&ldquo We believe this financing significantly strengthens Phytolon&rsquo s growth trajectory and long-term value creation potential. Trendlines and Consensus Business Group remain committed long-term shareholders of Phytolon,&rdquo says Trendlines&rsquo executive director and CEO, Haim Brosh.

Shares of Trendlines closed 0.3 cents higher, or 5.26% up at 6 cents on May 28.
 Useful To Me  Not Useful To Me
SmallSmall
Supreme
29-May-2026 09:15     
 
SmallSmall About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		That depends on whether you are trading or holding for EXITs

TraderBen      ( Date: 29-May-2026 09:14) Posted:

this one sai one la.. alwways gap up and sell down one.. 

 Useful To Me  Not Useful To Me
TraderBen
Supreme
29-May-2026 09:14     
 
TraderBen About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		this one sai one la.. alwways gap up and sell down one.. 
 Useful To Me  Not Useful To Me
SmallSmall
Supreme
29-May-2026 08:55     
 
SmallSmall About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		Trendlines Portfolio Company Phytolon Closes US$23.6 Million Series B to Commercialize its Innovative Natural Food Colors

&bull The 3-stage financing round was led by a strategic investor as demand for high quality natural colors accelerates globally &bull Earlier this year the FDA approved ' Beetroot Red' , Phytolon' s first product made by fermentation the effective date is subjected to FDA procedures Misgav, Israel &ndash 28 May 2026 &ndash The Trendlines Group Ltd. (SGX: 42T OTCQX: TRNLY), an investment group focused on agrifood and medtech innovation, is pleased to announce that portfolio company Phytolon Ltd. (&ldquo Phytolon&rdquo ), a biotechnology company pioneering fermentation-based natural color solutions, has announced the close of its US$23.6 Million Series B financing to commercialize its natural food colors in the United States. The round reflects growing market demand for highperforming, economic, and sustainable natural substitution to synthetic dyes.
 Useful To Me  Not Useful To Me
SmallSmall
Supreme
11-May-2026 21:18     
 
SmallSmall About Contact  Quote this Post!  
  x 0
  x 1

 Alert Admin 		$0.062-$0.063....time to accumulate.
This one risks vs returns is now in the returns' favours as more of its startups starts to reach commercialization stage.
Any buyouts or commercial tieups will see massive upswings in its share price.

 
 Useful To Me  Not Useful To Me
SmallSmall
Supreme
05-May-2026 10:26     
 
SmallSmall About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		This one looks unusually strong today. Usually will spike up then die off.
Today seems to be holding well so far. $0.065 +$0.003 Vol 14.4 mil

&ldquo This clearance represents a key milestone in Vensica Medical&rsquo s development and follows a number of key developments recently in our portfolio, emphasising the progress and maturity of our companies,&rdquo adds Haim Brosh, CEO of Trendlines.

SmallSmall      ( Date: 05-May-2026 08:15) Posted:

Trendlines portfolio company Vensica Medical&rsquo s needle-free bladder therapy progress into Phase two of clinical trial

 
The study will evaluate Vensica&rsquo s Vibe ultrasound-based, needle-free drug delivery system in combination with Xeomin for the treatment of overactive bladder (OAB). Photo: Bloomberg
 
 


The Trendlines Group Trendlines announced that its portfolio company, Vensica Medical, has secured the clearance from the US Food Drug Administration (FDA) on its investigational new drug (IND) application to initiate a Phase two clinical trial of ViXe.

According to Trendlines, the study will evaluate Vensica&rsquo s Vibe ultrasound-based, needle-free drug delivery system in combination with Xeomin for the treatment of overactive bladder (OAB).

Trendlines believes that the Phase two study will enrol approximately 210 patients across United States and Europe and this milestone triggers a contractual development milestone payment from its strategic partners.

Vensica Medical is supported by numerous investors and strategic partners, including Merz Pharma, Laborie, Israel Biotech Fund and Trendlines.

&ldquo We believe ViXe has the potential to overcome the barriers of needle-based delivery and deliver meaningful impact in urologic healthcare,&rdquo says Vensica Medical&rsquo s CEO, Avner Geva.

&ldquo This clearance represents a key milestone in Vensica Medical&rsquo s development and follows a number of key developments recently in our portfolio, emphasising the progress and maturity of our companies,&rdquo adds Haim Brosh, CEO of Trendlines.

 Useful To Me  Not Useful To Me
                                                         First   1-20 of 310   Older>   Last  



ShareJunction Version: 27 Nov 2020 ver- All Rights Reserved. Copyright ShareJunction Pte. Ltd. Disclaimer: All prices from are delayed. ShareJunction does not provide you with any financial advice. We are not into the business of providing any investment advice. See our Terms and Conditions and Privacy Policy of using this website. Data is delayed for varying periods of time depending on the exchange, but for at least 15 minutes. Copyright © SIX Financial Information Ltd. and its licensors. All Rights reserved. Further distribution and use by third parties prohibited. SIX Financial Information and its licensors make no warranty for information displayed and accept no liability for data and prices. SIX Financial Information reserves the right to adapt and/or alter this website at any time without prior notice.

Web design by FoundationFlux. Hosted with Signetique Cloud.